Tradestie Institutional Equity Comparison Engine
EQ vs INMB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EQ Overall Edge
EQ Captures Institutional Edge (2โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Momentum & Technical while INMB counters with relative strength in Options & Structure. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus INMB at N/M Forward P/E and 0.0% operating margin (+257.1% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against INMB sits in BREAKDOWN (61st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
EQ
EQ 1.5x vs INMB N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -52.3% vs +257.1%
Momentum & Technical Winner
EQ
1Y +12.0% vs -40.4% ยท 52W Pos 11% vs 0%
Options & Structure Winner
INMB
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (61st %ile IV)
EQ
NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap
$90.6M
1M Return
-21.13%
1Y Return
+12.0%
Forward P/E
1.5x
Unified AI Score
48.0 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
INMB
NASDAQ
INmune Bio Inc. Common stock
Biological Products, (No Disgnostic Substances)
$0.89
-13.19% 1D
Market Cap
$31.9M
1M Return
-44.47%
1Y Return
-40.39%
Forward P/E
N/M
Unified AI Score
45.4 / 100
HOLD
Tech 30.0
Fund 58.0
Flow 70.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EQ +12.0%
INMB -40.39%
Spread: +52.39 pp (EQ Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EQ Revenue | INMB Revenue | EQ Op. Margin | INMB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -111163.6% | INMB |
| FY2021 | N/A | $0M | N/A | -16106.6% | INMB |
| FY2022 | $20M | $0M | -393.9% | -6938.8% | EQ |
| FY2023 | $40M | $0M | -40.2% | -19187.7% | EQ |
| FY2024 | $40M | $0M | -20.1% | -304535.7% | EQ |
| FY2025 | N/A | $0M | N/A | -94766.0% | INMB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EQ | INMB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $90.6M | $31.9M | Larger Scale | EQ |
| Trailing P/E Ratio Valuation | 1.5x | N/M | Lower Multiple | EQ |
| Forward P/E Ratio Valuation | 1.5x | N/M | Lower Multiple | EQ |
| Revenue Growth (YoY) Growth | -52.3% | +257.1% | Higher Growth | INMB |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -59.0% | -76.7% | Higher ROE | EQ |
| 52-Week Range Position Momentum | 11% ($1โ$4) | 0% ($1โ$3) | Stronger Trend | EQ |
| Beta / 30D Volatility Risk Regime | 1.53ฮฒ ยท 93% Vol | 2.70ฮฒ ยท 85% Vol | Lower Realized Risk | INMB |
| Unified Institutional Score Composite Signal | 48.0 / 100 (HOLD) | 45.4 / 100 (HOLD) | Higher Composite | EQ |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EQ vs INMB Buy Guide
EQ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
INMB
BREAKDOWN
52d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
61st %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EQ nor INMB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.